menu
    • menu

    Company profile for Vyriad

    NEW Drugs in Dev: 5
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Vyriad is a clinical-stage company developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. The potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of research by dedicated researchers and clinicians at Mayo Clinic and the University of Miami. The Company has exclusive licenses to technologies discovered and validated at the Department o...
    Vyriad is a clinical-stage company developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. The potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of research by dedicated researchers and clinicians at Mayo Clinic and the University of Miami. The Company has exclusive licenses to technologies discovered and validated at the Department of Molecular Medicine that Vyriad CEO Dr. Stephen Russell founded at Mayo Clinic, along with its comprehensive oncolytic virotherapy program.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    VyriadUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2900 37th Street NW Building 110 Rochester, MN 55901
    Telephone
    Telephone
    507-289-0944
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vyriad.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vyriad Launches G-Link Platform for T-Cell Lentiviral Delivery
    Vyriad Launches G-Link Platform for T-Cell Lentiviral Delivery

    20 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-20/vyriad-launches-g-link-a-modular-platform-advancing-t-cell-targeted-lentiviral-vector-delivery-for

    PHARMIWEB
    20 May 2026
    Share Share
    Vyriad Secures $25M To Advance In Vivo CAR T Candidate To Clinic
    Vyriad Secures $25M To Advance In Vivo CAR T Candidate To Clinic

    23 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251223297085/en/Vyriad-Secures-Final-%2425M-Series-B-Tranche-to-Advance-In-Vivo-CAR-T-Candidate-into-Clinic

    BUSINESSWIRE
    23 Dec 2025
    Share Share
    Vyriad Unveils Lead In Vivo CAR-T VV169 at ASH 2025
    Vyriad Unveils Lead In Vivo CAR-T VV169 at ASH 2025

    16 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251216174554/en/Vyriad-Unveils-Lead-In-Vivo-CAR-T-Candidate-VV169-and-Data-Supporting-Future-Clinical-Development-During-ASH-2025

    BUSINESSWIRE
    16 Dec 2025
    Share Share
    Vyriad, Weizmann Sign License Pact For Gene Delivery Technology
    Vyriad, Weizmann Sign License Pact For Gene Delivery Technology

    02 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-02/vyriad-and-weizmann-institute-of-science-enter-exclusive-license-agreement-for-in-vivo-gene-delivery

    PHARMAWEB
    02 Sep 2025
    Share Share
    Novartis taps Vyriad’s viral vectors for in vivo T cell editing
    Novartis taps Vyriad’s viral vectors for in vivo T cell editing

    20 Nov 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/novartis-taps-vyriads-viral-vectors-develop-vivo-t-cell-editing

    FIERCE BIOTECH
    20 Nov 2024
    Share Share
    Vyriad Partners with Novartis to Develop In Vivo CAR-T Therapies
    Vyriad Partners with Novartis to Develop In Vivo CAR-T Therapies

    20 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vyriad-announces-strategic-collaboration-with-novartis-to-develop-in-vivo-car-t-cell-therapies-302310717.html

    PR NEWSWIRE
    20 Nov 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search